HACKENSACK, N.J. -- The Radiology Department at HackensackUMC is the first hospital in New Jersey, and one of only a few sites nationwide, to perform a revolutionary new procedure to detect recurrent prostate cancer using a radioisotope.
Called C-11 Choline, the procedure is intended for patients who have had a known diagnosis of prostate cancer, and previously were treated with radiation or surgery, said Michael Stifelman, M.D., chairman, Department of Urology, HackensackUMC and director of Urologic Oncology, John Theurer Cancer Center at HackensackUMC.
“This new test will not only tell us if there has been a reoccurrence of cancer, but it will also help us to identify where the cancer recurrence is,” Stifelman said.
C-11 Choline helps doctors detect sites of recurrent prostate cancer that conventional imaging, such as CAT or MRI scans, can’t. Patients receive an injection of Choline C-11 intravenously immediately followed by a PET/CT scan. Cancer cells, if present in the body, will readily absorb the C-11 Choline, and light up, pinpointing their exact location.
Pinpointing specific recurrent cancer sites within and/or outside the prostate allows physicians to more effectively target and treat recurrent prostate cancer.
In 2015, there were more than 220,000 new cases of prostate cancer in the United States and more than 27,000 deaths.
HackensackUMC is a member of Hackensack Meridian Health.
Click here to sign up for Daily Voice's free daily emails and news alerts.